(Reuters) – Pfizer has agreed to settle more than 10,000 lawsuits alleging cancer risks related to now-discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal.
The agreements cover cases in U.S. state courts but do not fully resolve Zantac’s claims, the report said, adding that financial details of the deals were not immediately available.
Pfizer (NYSE:) did not immediately respond to a Reuters request for comment.
In 2020, the US Food and Drug Administration asked drug makers to remove Zantac and its generic versions from the market after a cancer-causing substance called NDMA was found in samples of the drug.
Thousands of lawsuits have begun piling up in federal and state courts against Pfizer, GSK, Sanofi (NASDAQ:) and Boehringer Ingelheim.